Cocrystal Pharma, Inc. (COCP)
1.135
+0.02
(+2.25%)
USD |
NASDAQ |
Aug 25, 16:00
1.135
0.00 (0.00%)
After-Hours: 18:36
Cocrystal Pharma EPS Diluted (Quarterly) : -0.2295 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.2295 |
| March 31, 2026 | -0.1668 |
| December 31, 2025 | -0.176 |
| September 30, 2025 | -0.1864 |
| June 30, 2025 | -0.202 |
| March 31, 2025 | -0.2262 |
| December 31, 2024 | -0.321 |
| September 30, 2024 | -0.4854 |
| June 30, 2024 | -0.5252 |
| March 31, 2024 | -0.3888 |
| December 31, 2023 | -0.4388 |
| September 30, 2023 | -0.4102 |
| June 30, 2023 | -0.4139 |
| March 31, 2023 | -0.6372 |
| December 31, 2022 | -0.5527 |
| September 30, 2022 | -8.400 |
| June 30, 2022 | -3.007 |
| March 31, 2022 | -0.518 |
| December 31, 2021 | -0.4537 |
| September 30, 2021 | -0.4852 |
| June 30, 2021 | -0.5266 |
| March 31, 2021 | -0.4612 |
| December 31, 2020 | -0.2544 |
| September 30, 2020 | -0.5567 |
| June 30, 2020 | -0.8044 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.5732 |
| December 31, 2019 | -18.02 |
| September 30, 2019 | -0.6755 |
| June 30, 2019 | -0.5749 |
| March 31, 2019 | 1.174 |
| December 31, 2018 | -17.75 |
| September 30, 2018 | -0.7492 |
| June 30, 2018 | -0.60 |
| March 31, 2018 | -0.72 |
| December 31, 2017 | 3.60 |
| September 30, 2017 | -1.116 |
| June 30, 2017 | -0.4968 |
| March 31, 2017 | -1.285 |
| December 31, 2016 | -32.40 |
| September 30, 2016 | -0.9576 |
| June 30, 2016 | -1.649 |
| March 31, 2016 | -3.60 |
| December 31, 2015 | -14.40 |
| September 30, 2015 | -0.2628 |
| June 30, 2015 | -1.364 |
| March 31, 2015 | -14.40 |
| December 31, 2014 | -7.20 |
| September 30, 2014 | -3.60 |
| June 30, 2014 | -1.001 |
| March 31, 2014 | -0.414 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| CNBX Pharmaceuticals, Inc. | -0.0001 |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 2.578 |
| Fulcrum Therapeutics, Inc. | -0.3433 |
| Definium Therapeutics, Inc. | -1.436 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -3.164M |
| Revenue (Quarterly) | 0.105M |
| Total Expenses (Quarterly) | 3.269M |
| Enterprise Value | 14.40M |
| Gross Profit Margin (Quarterly) | 88.57% |
| Profit Margin (Quarterly) | -3.01K% |
| Earnings Yield | -66.85% |
| Normalized Earnings Yield | -66.85 |